ApprovedFDA approval

Avlayah (tividenofusp alfa-eknm)

Denali Therapeutics (DNLI)

Marketer take

Enters Hunter syndrome, where Elaprase has long been the standard enzyme therapy, so metabolic geneticists, lysosomal disease centers and families will look for clear differentiation; it was designed to reach the brain.

Sponsor company
Denali Therapeutics (DNLI)
Indication
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
Therapeutic area
Rare disease
Event
FDA approval
Date
Mar 24, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move